CN106692145B - Medicine for treating vascular dementia - Google Patents
Medicine for treating vascular dementia Download PDFInfo
- Publication number
- CN106692145B CN106692145B CN201710025127.2A CN201710025127A CN106692145B CN 106692145 B CN106692145 B CN 106692145B CN 201710025127 A CN201710025127 A CN 201710025127A CN 106692145 B CN106692145 B CN 106692145B
- Authority
- CN
- China
- Prior art keywords
- higenamine
- icariin
- vascular dementia
- preparation
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000004810 Vascular dementia Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title abstract description 9
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims abstract description 37
- WZRCQWQRFZITDX-UHFFFAOYSA-N (RS)-norcoclaurine Chemical compound C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-UHFFFAOYSA-N 0.000 claims abstract description 35
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims abstract description 32
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims abstract description 32
- WZRCQWQRFZITDX-AWEZNQCLSA-N Norcoclaurine Natural products C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 13
- 230000002146 bilateral effect Effects 0.000 description 12
- 230000015654 memory Effects 0.000 description 8
- 230000010410 reperfusion Effects 0.000 description 8
- 210000001168 carotid artery common Anatomy 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Abstract
The invention discloses a drug for treating vascular dementia, and particularly discloses a combined drug for treating vascular dementia, which comprises higenamine and icariin which are used for simultaneous or separate administration of unit preparations with the same or different specifications, and a pharmaceutically acceptable carrier. The invention also discloses a pharmaceutical composition for treating vascular dementia, which is a preparation prepared from the following raw materials in parts by weight: the weight ratio of the higenamine to the icariin is 1: (1-10). The invention also discloses a preparation method and application of the composition. The invention combines the higenamine and the icariin for use, can effectively treat the vascular dementia and has good application prospect.
Description
Technical Field
The invention relates to a medicine for treating vascular dementia.
Background
Dementia is a progressive cognitive function deterioration caused by brain injury or disease, the deterioration range is far higher than the normal aging progress, especially, memory, attention, language, problem solving ability and the like are influenced, people and things can not be distinguished when the dementia is serious, and the dementia mainly comprises Alzheimer's Disease (AD), Vascular Dementia (VD), mixed dementia and other types.
The vascular dementia is a serious cognitive dysfunction syndrome caused by cerebral vascular diseases such as hypoperfusion of brain areas such as memory, cognition and behavior and the like caused by cerebral vascular accidents such as ischemic stroke, hemorrhagic stroke and the like, the prevalence rate of VD in China is 1.1-3.0%, and the annual incidence rate is 5-9/1000.
In contrast to the irreversible development of AD, vascular dementia is a type of dementia that can be prevented and treated, and the current therapeutic drugs mainly include: lipid regulating medicine, cholinergic medicine, medicine for promoting brain metabolism and improving brain circulation, etc. The action mechanisms of the medicines are different, but the curative effect of the medicines is not ideal due to the complex cause of the vascular dementia.
In addition, some traditional Chinese medicine extracts are considered to be capable of treating vascular dementia, and all the extracts achieve certain curative effects: such as saponins such as panax notoginseng saponins, flavonoids such as puerarin, alkaloids such as huperzine A and the like, but most of the saponins are still in the experimental research stage.
Therefore, the search for new drugs effective against vascular dementia has significant social and economic values.
Disclosure of Invention
The invention aims to provide a combined medicine and a composition for treating vascular dementia.
The invention relates to a combined medicament for treating vascular dementia, which contains higenamine and icariin which are prepared into unit preparations with the same or different specifications and are used for simultaneous or separate administration, and a pharmaceutically acceptable carrier.
Wherein the weight ratio of the higenamine to the icariin is 1: (1-10).
Further, the proportion of the higenamine and the icariin is 1: (5-10), more preferably 1: 5.
the invention also provides a pharmaceutical composition for treating vascular dementia, which is a preparation prepared from the following raw materials in parts by weight: the weight ratio of the higenamine to the icariin is 1: (1-10).
Further, the weight ratio of the higenamine to the icariin is 1: (5-10), more preferably 1: 5.
the composition is prepared into a preparation by taking higenamine and icariin as active ingredients and adding pharmaceutically common auxiliary materials or auxiliary materials.
Wherein the formulation is an oral formulation.
The invention also provides a preparation method of the pharmaceutical composition, which is characterized by comprising the following steps: the method comprises the following operation steps:
(1) weighing the raw materials according to the weight ratio;
(2) the preparation is prepared by taking the medicinal powder of the raw materials, or the water or ethanol extract of the raw materials as an active ingredient, and adding pharmaceutically common auxiliary materials or auxiliary materials.
The invention also provides the application of the combined medicine and the pharmaceutical composition in preparing medicines for treating vascular dementia.
The invention also provides application of the higenamine in preparing a medicament for treating vascular dementia.
The invention proves that the composition of higenamine and icariin has definite drug effect on the aspect of treating vascular dementia, and has good clinical application prospect when being used for preparing corresponding drugs, and when the composition of higenamine and icariin in the weight ratio of 1:5 is used, the higenamine and icariin have the effect under the same action dosage because the higenamine and the icariin are used independently, so that the higenamine and the icariin play a synergistic effect under the mixture ratio.
The present invention is described in further detail with reference to the following embodiments, but the present invention is not limited thereto, and various other modifications, substitutions and alterations can be made without departing from the basic technical idea of the present invention based on the above-mentioned contents of the present invention and common technical knowledge and conventional means in the art.
Detailed Description
EXAMPLE 1 preparation of a pharmaceutical composition of the invention
Mixing the hizome removing alkaloid 10g and the icariin 10g, and adding pharmaceutically acceptable auxiliary materials.
EXAMPLE 2 preparation of pharmaceutical compositions of the invention
Mixing the hizome removing 10g and the icariin 50g, and adding pharmaceutically acceptable auxiliary materials.
EXAMPLE 3 preparation of a pharmaceutical composition of the invention
Mixing the hizome removing 10g and icariin 100g, and adding pharmaceutically acceptable adjuvants.
The beneficial effects of the invention are demonstrated in the following manner by way of experimental examples:
experimental example 1 Effect of the drug of the present invention on treating vascular dementia
1. Experimental Material
The medicine composition of the invention comprises the following components: mixing higenamine and icariin with purity of more than 98% respectively by HPCL detection, mixing the higenamine and icariin according to weight ratio of 1:1, 1:5 and 1:10, and preparing into suspension with required concentration with 0.5% Carboxymethyl Cellulose (CMC) for use.
Comparison products: oxiracetam (ORC, Shiyao group), was formulated into a suspension of the required concentration with 0.5% CMC just prior to use.
2. Experimental methods
2.1 Effect of the composition on Passive avoidance of VD model mice by bilateral common carotid artery ischemia reperfusion (dark box avoidance method)
160 SPF-grade Kunming mice with 18-22g male bodies are randomly divided into 8 groups according to weight, namely a composition (1:1) group, a composition (1:5) group, a composition (1:10) group, a higenamine group, an icariin group, a positive control (ORC) group, a model control group and a sham operation control group. Except for the sham control group, each group was occluded (10min) -opened (20min) by bilateral common carotid artery, repeated three times, and the VD model was replicated; the sham group only isolated bilateral common carotid arteries without clipping and reperfusion. The test substance and the reference substance are administered by intragastric administration on the next day after operation, the dosage is 200mg/kg, the administration amount is 0.1ml/10g once a day, and the administration is continued for 30 days; sham groups were given equal amounts of solvent simultaneously. Performing dark box avoiding memory acquisition training after administration for 1h on the 31 st day; dark box memory tests were performed 1h after the day 32 dosing.
2.2 Effect of the composition on active avoidance of VD model mice by bilateral common carotid ischemia reperfusion (shuttle Box method)
Taking 200 male Kunming mice of 18-22g, and performing first round shuttle box conditional stimulation-unconditional stimulation memory acquisition training for 3 consecutive days; on the fourth day, only SPF-class Kunming mice 160 with an Active Avoidance Response (AAR) rate greater than 80% were selected for testing. The qualified animals are divided into 8 groups according to weight layer, namely a composition (1:1) group, a composition (1:5) group, a composition (1:10) group, a higenamine group, an icariin group, a positive control (ORC) group, a model control group and a pseudo-operation control group. Except for the sham control group, each group was occluded (10min) -opened (20min) by bilateral common carotid artery, repeated three times, and the VD model was replicated; the sham group only isolated bilateral common carotid arteries without clipping and reperfusion. The test substance and the reference substance are administered by intragastric administration on the next day after operation, the dosage is 200mg/kg, the administration amount is 0.1ml/10g once a day, and the administration is continued for 30 days; sham groups were given equal amounts of solvent simultaneously. Performing a second round of shuttle box conditional stimulation-unconditional stimulation memory acquisition training on days 26-28 for 3 consecutive days; performing a dark box memory test after 1h of administration on the 29 th day, and recording the number of active avoidance times in 20 shuttling; the above test was repeated 1h after the 30 th day dosing.
3. Results of the experiment
3.1 Effect on passive avoidance of VD model mouse caused by bilateral common carotid artery ischemia-reperfusion (dark box avoidance method)
The results are shown in table 1:
TABLE 1 Effect of the compositions on Passive avoidance of VD model mice by bilateral common carotid ischemia reperfusion (dark box avoidance method)
Compared with the model control group, P is less than 0.05, P is less than 0.01, compared with the icariin group, △ P is less than 0.05, and less than 20 animals die after surgery.
The results show that any component in the composition applied independently has a certain effect, but the icariin group has no statistical difference; the passive avoidance response of animals in the composition groups with different proportions is obviously better than that of the model control group. The results suggest that the composition has the effect of improving experimental VD, and the 1:5 group is superior to the single use of icariin and shows a superior action trend compared with the higenamine group.
3.2 Effect on active avoidance of VD model mice by bilateral common carotid artery ischemia-reperfusion (shuttle box method)
The results are shown in table 2:
TABLE 2 Effect of the compositions on active avoidance of VD model mice by bilateral common carotid ischemia reperfusion (shuttle Box method)
Compared with the model control group, P is less than 0.05, P is less than 0.01, △ P is less than 0.05 compared with the icariin group, ⊙ P is less than 0.05 compared with the higenamine group, and less than 20 animals die after the operation.
The results show that bilateral common artery clamp reperfusion can lead to weakening of active avoidance behavior caused by condition stimulation, and the AAR of the bilateral common artery clamp reperfusion is obviously reduced (P < 0.01). Any component in the composition applied independently has a certain effect, but the higenamine group has no statistical difference; the passive avoidance response of animals in the composition groups with different proportions is obviously better than that of the model control group. The results suggest that the composition has improved experimental VD and that the 1:5 group is superior to the single ingredient in the composition used alone.
The results show that the higenamine and the icariin are used in combination, the cognitive disorder such as experimental VD memory, learning and the like is obviously improved, and the vascular dementia is exactly treated, and when the higenamine and the icariin are used in the composition according to the weight ratio of 1:5, the higenamine and the icariin are used independently under the same action dosage, so that the higenamine and the icariin play a synergistic effect under the mixture ratio.
Claims (12)
1. A combined medicine for treating vascular dementia is characterized in that: it contains higenamine and icariin which are used for simultaneous or separate administration and are made into unit preparations with same or different specifications, and a pharmaceutically acceptable carrier.
2. The combination of claim 1, wherein: the weight ratio of the higenamine to the icariin is 1: (1-10).
3. The combination as claimed in claim 2, wherein: the proportion of the higenamine and the icariin is 1: (5-10).
4. The combination as claimed in claim 3, wherein the ratio of higenamine to icariin is 1: 5.
5. a medicine composition for treating vascular dementia is characterized in that: the preparation is prepared from the following raw materials in parts by weight: the weight ratio of the higenamine to the icariin is 1: (1-10).
6. The pharmaceutical composition of claim 5, wherein: the weight ratio of the higenamine to the icariin is 1: (5-10).
7. The pharmaceutical composition according to claim 6, wherein the weight ratio of higenamine to icariin is 1: 5.
8. the pharmaceutical composition according to any one of claims 5 to 7, wherein: the preparation is prepared by taking higenamine and icariin as active ingredients and adding pharmaceutically common auxiliary materials or auxiliary materials.
9. The pharmaceutical composition of claim 8, wherein: the preparation is an oral preparation.
10. A process for the preparation of a pharmaceutical composition according to any one of claims 5 to 9, characterized in that: the method comprises the following operation steps:
(1) weighing the raw materials according to the weight ratio;
(2) the preparation is prepared by taking the medicinal powder of the raw materials, or the water or ethanol extract of the raw materials as an active ingredient, and adding pharmaceutically common auxiliary materials or auxiliary materials.
11. Use of a combination according to any one of claims 1 to 4 and a pharmaceutical composition according to any one of claims 5 to 9 in the manufacture of a medicament for the treatment of vascular dementia.
12. Use of higenamine in preparing medicine for treating vascular dementia is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710025127.2A CN106692145B (en) | 2017-01-13 | 2017-01-13 | Medicine for treating vascular dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710025127.2A CN106692145B (en) | 2017-01-13 | 2017-01-13 | Medicine for treating vascular dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106692145A CN106692145A (en) | 2017-05-24 |
| CN106692145B true CN106692145B (en) | 2020-03-20 |
Family
ID=58908367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710025127.2A Active CN106692145B (en) | 2017-01-13 | 2017-01-13 | Medicine for treating vascular dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692145B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638823A (en) * | 2019-10-25 | 2020-01-03 | 贵州中医药大学 | Application of icariin in preparation of medicine for treating vascular dementia |
| CN111803502A (en) * | 2020-06-30 | 2020-10-23 | 安域生物制药(杭州)有限公司 | Application of higenamine in preventing and treating Alzheimer disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626103A (en) * | 2004-08-10 | 2005-06-15 | 浙江大学 | Combination of medication of containing general saponin of notoginseng and icariin as well as usage |
-
2017
- 2017-01-13 CN CN201710025127.2A patent/CN106692145B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1626103A (en) * | 2004-08-10 | 2005-06-15 | 浙江大学 | Combination of medication of containing general saponin of notoginseng and icariin as well as usage |
Non-Patent Citations (1)
| Title |
|---|
| 张渝华.止血用生药的止血效果.《国外药学•植物药分册》.1982,第8卷(第5期),第45-46页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106692145A (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101498780B1 (en) | Composition for preventing or treating hangover | |
| KR20100117074A (en) | Composition containing capsicum for treating a skin disorder | |
| KR102231129B1 (en) | Combination of Valerian Root Extract and Lavender Oil for Use in the Treatment of Sleep Disorders | |
| CN106692145B (en) | Medicine for treating vascular dementia | |
| KR20100091206A (en) | Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression | |
| KR20140120667A (en) | A composition comprising the extract of Salix genus plant for treating and preventing neuro-degenerative disease | |
| DE112022002721T5 (en) | COMPOSITION OF A TRADITIONAL CHINESE MEDICINAL EXTRACT FOR THE PREVENTION AND TREATMENT OF INFLUENZA, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | |
| KR20170062781A (en) | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function | |
| JPH0327318A (en) | Drug for allergic rhinitis | |
| RU2485965C2 (en) | Compartment-specific dual combination of herbal extracts of ginkgo biloba and ginseng | |
| KR20160043430A (en) | Composition for preventing hair loss, promoting hair generation, or enhancing moist and glossy of hair and manufacturing method thereof | |
| CN104644698B (en) | A kind of product for preventing senile dementia and preparation method thereof | |
| EP2956151B1 (en) | Use of extracts from calendula for the treatment and prevention of disorders and impairments of cognitive and mental functions | |
| KR20130010042A (en) | A composition comprising the dried powder of black ginseng and the extract thereof for treating and preventing neuro-degenerative disease | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| KR20010009653A (en) | Composition for treating sexual dysfunction | |
| WO2016185509A1 (en) | Ginsenoside composition | |
| JP6698034B2 (en) | Oral composition for improving systemic symptoms such as chills | |
| EP3006026A1 (en) | Pharmaceutical composition for treating anxiety containing l-theanine and baicalein | |
| BOLESŁAWSKA et al. | HERBAL RESOURCES IN THE MEDICATION OF DEPRESSION DURING PANDEMIC COVID-19. | |
| US20130280354A1 (en) | Composition and Method for Using Sage | |
| Jahani et al. | The effects of hydro alcoholic-extracts garlic on depression induced by reserpine in rats | |
| US20210299097A1 (en) | Compositions for a dietary supplement to improve sleep | |
| Kumar et al. | A Comparative Study on Effect of Oral Administration of Turmeric and Nutmeg on Memory Boosting and Regaining in Wistar Albino Rats | |
| KR101946282B1 (en) | A composition for preventing or treating breast cancer comprising herbal ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231009 Address after: 519000 room 407, building 1, No. 36, Doukou Road, Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park, Hengqin new area, Zhuhai City, Guangdong Province Patentee after: Zhuhai Hengqin Aoye Health Technology Co.,Ltd. Address before: 610041 No. 4, South Renmin Road, Sichuan, Chengdu province 51 Patentee before: SICHUAN ACADEMY OF CHINESE MEDICINE SCIENCES |
|
| TR01 | Transfer of patent right |